Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model

Autor: Laurent Meijer, Gordon B. Mills, Khandan Keyomarsi, Donald H. Lambert, Laura A. Lambert, Na Qiao, Kelly K. Hunt
Přispěvatelé: Biogéosciences [UMR 6282] (BGS), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Program in integrative biology. Research Institute, The Hospital for sick children [Toronto] (SickKids), Unité de Chimie Pharmaceutique et Radiopharmacie (UCL-CMFA 7340), Université Catholique de Louvain = Catholic University of Louvain (UCL), School of Environmental Sciences [Norwich], University of East Anglia [Norwich] (UEA), Molécules et cibles thérapeutiques (MCT), Station biologique de Roscoff [Roscoff] (SBR), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Biogéosciences [UMR 6282] [Dijon] (BGS), Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Biogéosciences [Dijon] ( BGS ), AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), The Hospital for Sick Children, Unité de Chimie Pharmaceutique et Radiopharmacie ( UCL-CMFA 7340 ), Université Catholique de Louvain ( UCL ), University of East Anglia [Norwich] ( UEA ), Molécules et cibles thérapeutiques ( MCT ), Centre National de la Recherche Scientifique ( CNRS )
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Cancer Research
Cell cycle checkpoint
MESH : Antineoplastic Combined Chemotherapy Protocols
medicine.medical_treatment
Apoptosis
MESH : Models
Biological

Pharmacology
MESH: Drug Synergism
0302 clinical medicine
MESH : Tumor Cells
Cultured

MESH : Cytotoxins
Antineoplastic Combined Chemotherapy Protocols
Tumor Cells
Cultured

MESH : G2 Phase
MESH : Purines
Cytotoxicity
Tumor Stem Cell Assay
0303 health sciences
Cytotoxins
MESH: Tumor Stem Cell Assay
Drug Synergism
Sarcoma
MESH: Purines
Cell cycle
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
Oncology
030220 oncology & carcinogenesis
MESH: Cytotoxins
medicine.drug
G2 Phase
MESH : Drug Synergism
MESH : Tumor Stem Cell Assay
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
Biology
MESH : Sarcoma
Models
Biological

Article
03 medical and health sciences
MESH: Doxorubicin
Therapeutic index
medicine
Autophagy
Roscovitine
MESH : Doxorubicin
MESH: Autophagy
Humans
Doxorubicin
MESH: Tumor Cells
Cultured

030304 developmental biology
Chemotherapy
MESH: Humans
[ SDV.BC ] Life Sciences [q-bio]/Cellular Biology
MESH: Apoptosis
MESH : Humans
MESH: Models
Biological

MESH : Autophagy
MESH: G2 Phase
Purines
MESH: Sarcoma
MESH : Apoptosis
Zdroj: Cancer Research
Cancer Research, 2008, 68 (19), pp.7966-74. ⟨10.1158/0008-5472.CAN-08-1333⟩
Cancer Research, American Association for Cancer Research, 2008, 68 (19), pp.7966-74. ⟨10.1158/0008-5472.CAN-08-1333⟩
Cancer Research, American Association for Cancer Research, 2008, 68 (19), pp.7966-74. 〈10.1158/0008-5472.CAN-08-1333〉
ISSN: 0008-5472
1538-7445
DOI: 10.1158/0008-5472.CAN-08-1333⟩
Popis: Doxorubicin is a genotoxic chemotherapy agent used in treatment of a wide variety of cancers. Significant clinical side effects, including cardiac toxicity and myelosuppression, severely limit the therapeutic index of this commonly used agent and methods which improve doxorubicin efficacy could benefit many patients. Because doxorubicin cytotoxicity is cell cycle specific, the cell cycle is a rational target to enhance its efficacy. We examined the direct, cyclin-dependent kinase inhibitor roscovitine as a means of enhancing doxorubicin cytotoxicity. This study showed synergistic cytotoxicity between doxorubicin and roscovitine in three sarcoma cell lines: SW-982 (synovial sarcoma), U2OS-LC3-GFP (osteosarcoma), and SK-LMS-1 (uterine leiomyosarcoma), but not the fibroblast cell line WI38. The combined treatment of doxorubicin and roscovitine was associated with a prolonged G2-M cell cycle arrest in the three sarcoma cell lines. Using three different methods for detecting apoptosis, our results revealed that apoptotic cell death did not account for the synergistic cytotoxicity between doxorubicin and roscovitine. However, morphologic changes observed by light microscopy and increased cytoplasmic LC3-GFP puncta in U20S-LC3-GFP cells after the combined treatment suggested the induction of autophagy. Induction of autophagy was also shown in SW-982 and SK-LMS-1 cells treated with both doxorubicin and roscovitine by acridine orange staining. These results suggest a novel role of autophagy in the enhanced cytotoxicity by cell cycle inhibition after genotoxic injury in tumor cells. Further investigation of this enhanced cytotoxicity as a treatment strategy for sarcomas is warranted. [Cancer Res 2008;68(19):7966–74]
Databáze: OpenAIRE